“Blockade Medical’s responsiveness to clinical needs and ability to deliver new products to the market in a very short period of time is impressive. The enhanced first loop design of the New Barricade Framing Coil will expand the types of aneurysms I can now treat with the Barricade Coil System,” said Adnan Siddiqui, M.D., Ph.D., F.A.H.A., vice chairman and associate professor in the Department of Neurosurgery at the State University of New York in Buffalo.
The Barricade Coil System is an embolization coil line designed to endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels. The Barricade Coil System is a comprehensive bare platinum coil line available in framing, filling and finishing shapes. The Barricade Coil System received CE mark approval in July 2012 and FDA 510(k) clearance in March 2013.
“We are very proud of the enhancements to the Barricade Coil Line that we have delivered to the market in the past year including a handheld detachment cable set, longer coils and the recent approval of the enhanced Framing and Complex Finishing Coils," Blockade Medical’s President and Chief Technology Officer Dave Ferrera said.
“In my clinical experience, the existing Barricade Finishing Coil delivers best in class softness and deliverability from a helical finishing coil. The new Complex Finishing coil should provide even more effective finishing of aneurysms due to its unique shape and is a clinically relevant addition to the product line,” said Spiros Blackburn, M.D., assistant professor of Neurosurgery at the University of Florida College of Medicine in Gainesville.
Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and related disease of the neurovascular system. The company manufactures the Barricade Coil System in the United States and is based in Irvine, Calif.